JNJ Posts Strong Q2, Raises Outlook; Key Risks Persist

What happened

Johnson & Johnson reported strong second-quarter 2026 results and raised its full-year outlook, citing portfolio depth and pipeline momentum. The company's performance was driven by oncology growth in DARZALEX and CARVYKTI, which partially offset the ongoing STELARA biosimilar erosion. However, the DeepValue master report flags that the next 3-6 months contain discrete downside catalysts, including the CVS Caremark formulary shift on July 1, 2026, and talc evidentiary rulings. The raised guidance provides some near-term comfort but does not resolve the core risks: STELARA erosion may accelerate post-CVS, and talc liabilities remain unbounded. Investors should note that the stock still trades at a P/E of 26.5 with no margin of safety against these asymmetric risks, supporting a cautious stance.

Implication

The raised guidance and strong Q2 performance provide a positive data point, but the thesis hinges on upcoming catalysts. The stock's current price embeds confidence that STELARA erosion stays orderly and talc remains contained – neither of which is proven. A better entry may emerge after the CVS formulary impact is quantified in Q3 results or if talc risks escalate. Maintain a WAIT rating with attractive entry at $200.

Thesis delta

The Q2 beat and raised outlook modestly reduce near-term downside risk, but they do not alter the central investment thesis that the next 3-6 months contain critical downside catalysts before offsets can dominate. The WAIT rating is maintained.